All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Semaglutide Results After 18 Months: What to Expect

What do semaglutide results after 18 months look like? Review long-term clinical data from STEP trials, weight maintenance strategies, and what comes next.

By Dr. Michael Torres, MD|Reviewed by Dr. David Kim, MD, FACE||

Medically Reviewed

Written by Dr. Michael Torres, MD · Reviewed by Dr. David Kim, MD, FACE

Semaglutide Results After 18 Months: What to Expect custom 2026 header image for GLP-1 Weight Loss
Custom header image for Semaglutide Results After 18 Months: What to Expect, GLP-1 Weight Loss, and better treatment decision-making.
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Search and AI answer brief

Practical answer: Semaglutide Results After 18 Months: What to Expect

What do semaglutide results after 18 months look like? Review long-term clinical data from STEP trials, weight maintenance strategies, and what comes next.

Short answer

What do semaglutide results after 18 months look like? Review long-term clinical data from STEP trials, weight maintenance strategies, and what comes next.

Search intent

This page answers a specific GLP-1 Weight Loss question rather than a generic overview.

What to verify

semaglutide, tirzepatide, retatrutide, cash price and coverage terms

How to use it

Use this information to prepare sharper questions for a licensed provider.

Key Takeaway

What do semaglutide results after 18 months look like? Review long-term clinical data from STEP trials, weight maintenance strategies, and what comes next.

By the time you reach 18 months on semaglutide, you're well past the titration phase and into genuine long-term treatment territory. Knowing what semaglutide results after 18 months look like helps you make informed decisions about continuing, adjusting, or improving your treatment. We have examined the extended clinical trial data and real-world outcomes to give you a clear picture.

What the Long-Term Data Shows

The most relevant clinical data for 18-month semaglutide results comes from the STEP trial program:

  • STEP 1[1] (68 weeks / ~16 months): Participants on semaglutide 2.4 mg lost an average of 14.9% of body weight[1]. For a 230-pound person, that's roughly 34 pounds .
  • STEP 5 (104 weeks / 2 years): This extended trial showed sustained weight loss of approximately 15.2% of body weight at 2 year[2]s. At the 18-month mark (78 weeks), weight loss had largely plateaued, meaning most patients had reached their maximum benefit .
  • STEP 3 (with intensive behavioral therapy): Patients who combined semaglutide with structured lifestyle counseling lost up to 16% of body weight, with results holding at 18 months.

The consistent finding across these trials is that weight loss with semaglutide reaches a plateau between months 12 and 18. After that, the focus shifts from losing weight to maintaining it.

Timeline: From Start to 18 Months

  • Months 1 to 4 (titration): Gradual dose escalation from 0.25 mg to 2.4 mg. Weight loss of 4 to 10 pounds. Body adjusting to medication.
  • Months 5 to 8 (active loss): Fastest rate of weight loss. Roughly 1 to 2 pounds per week. Cumulative loss of 15 to 25 pounds.
  • Months 9 to 12 (continued loss, slowing): Rate gradually declines. Cumulative loss of 25 to 35 pounds. Metabolic adaptation begins.
  • Months 13 to 15 (approaching plateau): Weight loss slows considerably. Cumulative loss of 30 to 38 pounds. Focus shifts toward habit consolidation.
  • Months 16 to 18 (plateau/maintenance): Most patients have reached or are very close to their maximum weight loss. Cumulative loss of 30 to 40+ pounds. The body has established a new metabolic setpoint.

Health Improvements Beyond Weight at 18 Months

By 18 months, many patients experience meaningful improvements across multiple health markers:

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →
GLP-1 Weight Loss Results by Medication Mean Body Weight Loss (%) 0 6 12 18 24 22 15 8 24 Tirzepatide Semaglutide Liraglutide Retatrutide Based on published STEP and SURMOUNT trial data
GLP-1 Weight Loss Results by Medication. Based on published STEP and SURMOUNT trial data.
View data table
Bar chart showing glp-1 weight loss results by medication: Tirzepatide (22), Semaglutide (15), Liraglutide (8), Retatrutide (24)
CategoryMean Body Weight Loss (%)Detail
Tirzepatide22~22% body weight at 72 wks
Semaglutide15~15% body weight at 68 wks
Liraglutide8~8% body weight at 56 wks
Retatrutide24~24% in Phase 2 trial
Illustration for Semaglutide Results After 18 Months: What to Expect
  • Blood sugar: A1C reductions of 1.0% to 1.8% in patients with prediabetes or type 2 diabetes .
  • Cardiovascular health: The SELECT trial[4] demonstrated a 20% reduction in major adverse cardiovascular[4] events with semaglutide 2.4 mg over a median follow-up of 40 months .
  • Blood pressure: Systolic reductions of 3 to 6 mmHg are commonly observed.
  • Liver health: Improvements in liver fat content and ALT levels, particularly relevant for patients with NAFLD .
  • Sleep quality: Reduced sleep apnea severity and improved sleep patterns are frequently reported by patients who lose 10% or more of body weight.
  • Joint pain: Lower mechanical stress on knees, hips, and ankles often results in notable pain reduction.

The Plateau Phase: What Is Happening

It's completely normal for weight loss to plateau around months 12 to 18. This doesn't mean semaglutide has stopped working. Here is what is actually happening: For a complete cost breakdown, see our affordable GLP-1 options.

  • Metabolic adaptation: As you weigh less, your body burns fewer calories at rest. The caloric deficit that initially drove weight loss narrows.
  • Hormonal rebalancing: Leptin and ghrelin levels adjust to your new weight, influencing hunger and satiety signals.
  • New equilibrium: Your body has found a balance between the appetite-suppressing effects of semaglutide and your caloric needs at a lower weight.

The medication continues to prevent weight regain, which is itself a major benefit. Without continued treatment, the body's natural drive to return to its previous weight is strong .

What to Do at the 18-Month Mark

  • Review your labs: Get thorough bloodwork including A1C, lipid panel, liver enzymes, and kidney function. Compare to your baseline values.
  • Reassess your dose: If you're maintaining well, your provider might explore whether a slightly lower dose could sustain results with fewer side effects.
  • Evaluate body composition: A DEXA scan can reveal how much lean mass you have preserved. If muscle loss is significant, adjust your exercise and protein intake.
  • Strengthen lifestyle habits: By 18 months, the habits you have built should be able to support a good portion of your weight management independently.
  • Plan for the long term: Discuss with your provider whether continued treatment, dose reduction, or a structured taper is appropriate for your situation.

Frequently Asked Questions

Should I stay on semaglutide after 18 months?

For most patients, continuing treatment is advisable. The STEP 1 extension trial showed that patients who stopped semaglutide regained about two-thirds of their lost weight within a year . Long-term treatment helps maintain results.

Can I switch to a different medication at 18 months?

Some patients who plateau on semaglutide explore switching to tirzepatide (Mounjaro/Zepbound), which has shown greater weight loss in head-to-head comparisons. Your provider can guide this transition based on your response and goals.

Is it safe to take semaglutide for 18 months or longer?

Long-term safety data from trials extending to 2+ years and real-world use supports ongoing treatment. The SELECT trial followed patients for up to 5 years and found a favorable safety profile . Regular monitoring by your physician remains important .

Why has my weight loss completely stopped?

A true plateau lasting more than 6 to 8 weeks may warrant a conversation with your provider. Possible strategies include increasing physical activity, adjusting macronutrient ratios, addressing sleep or stress issues, or evaluating whether a dose adjustment or medication switch could help.

Will I need a higher dose to keep losing weight?

If you're already on the maximum dose (2.4 mg for Wegovy, or 2.0 mg for Ozempic), there's no approved higher dose. At that point, additional weight loss depends on lifestyle improvement or considering a different medication class.

Medical References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
  2. Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
  3. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]

Continue Your Progress with Expert Guidance

Reaching 18 months on semaglutide is a significant accomplishment. If you're maintaining your results, looking to break through a plateau, or considering your next steps, working with a knowledgeable provider makes all the difference. FormBlends offers ongoing clinical support for patients at every stage of their GLP-1 process.

Schedule a follow-up consultation to plan your next phase of treatment.

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-04-01
FormBlends review
Found official source
Official source
Retatrutide evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Semaglutide Results After 18 Months: What to Expect, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialSemaglutide evidence2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight

Supports head-to-head context when pages compare older and newer GLP-1 options.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Systematic reviewGLP-1 class evidence2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition

Supports body-composition, lean-mass, and metabolic-risk context.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

Used as a class-level evidence anchor when no more specific citation group matches.

PubMed

Provider decision path

Use local research to choose a safer review path

Direct answer

Semaglutide Results After 18 Months: What to Expect is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

FormBlends Editorial Context

Reviewed May 14, 2026

What do semaglutide results after 18 months look like? Review long-term clinical data from STEP trials, weight maintenance strategies, and what comes next. "Semaglutide Results After 18 Months: What to Expect" works best as a practical checklist for the next conversation. It focuses on patient education and clinical context, then narrows the issue through semaglutide, provider access. With 7 sections, the FAQ can reveal what readers usually miss. Use the page to prepare, then verify the personal medical pieces with a licensed clinician.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Semaglutide Results After 18 Months

Semaglutide Results After 18 Months now carries extra 2026 context around semaglutide, tirzepatide, retatrutide, cash-pay pricing, safety signals, results, because those are the subtopics readers tend to compare before they trust a medical or wellness recommendation.

Instead of adding filler, this page keeps the named treatment terms, practical verification points, and next-step questions close to semaglutide results after 18 months what to expect.

Readers should use the section to check current eligibility, pharmacy or provider policies, and safety questions with a licensed professional before acting.

Semaglutide Results After 18 Months custom 2026 image for glp-1 weight loss on FormBlends

Custom 2026 image for Semaglutide Results After 18 Months, glp-1 weight loss, and better treatment decision-making.

Image description: Unique image for this page covering Semaglutide Results After 18 Months, glp-1 weight loss, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by Dr. Michael Torres, MD

Endocrinologist. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by Dr. David Kim, MD, FACE for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $299/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.